ICD-10 Coding for Myeloproliferative Disorder(D47.1, D47.1B, D47.1C)
Explore detailed ICD-10 coding guidelines for myeloproliferative disorders, including Polycythemia Vera and Essential Thrombocythemia. Learn about documentation requirements and coding pitfalls.
Complete code families applicable to Myeloproliferative Disorder
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| D47.1 | Chronic myeloproliferative disease | Use for unspecified or unclassifiable myeloproliferative disorders. |
|
| D45 | Polycythemia vera | Use when polycythemia vera is confirmed by lab tests. |
|
| D47.3 | Essential thrombocythemia | Use when essential thrombocythemia is confirmed by exclusion of reactive causes. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutMyeloproliferative Disorder
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Myeloproliferative Disorder.
Using D47.1 for all myeloproliferative disorders.
Impact
Clinical: Misrepresentation of patient's condition., Regulatory: Potential audit issues., Financial: Incorrect reimbursement rates.
Mitigation
Verify specific subtype before coding., Consult clinical documentation.
Assuming hypercoagulable state from thrombosis alone.
Impact
Reimbursement: Incorrect coding can lead to denied claims., Compliance: Non-compliance with coding guidelines., Data Quality: Inaccurate clinical data representation.
Mitigation
Require explicit documentation of hypercoagulability.
Code specificity
Impact
Risk of using unspecified codes without supporting documentation.
Mitigation
Require detailed clinical documentation and lab results.